Confirming a pretty active recent rumor mill in the generic and specialty drug space, Actavis (NYSE:ACT) announced on Monday that it had reached an agreement to acquire Warner Chilcott (Nasdaq:WCRX) in an all-stock deal. This deal should bring real long-term value for Actavis, while giving the owners of long-struggling Warner Chilcott an honorable exit.
The Deal To Be
Assuming that the deal gets the request approvals and a rival suitor doesn't break things up, Actavis will acquire Warner Chilcott in an $8.5 billion all-stock deal that values Warner Chilcott at $20.08 a share – a roughly 5% premium to Friday's close, but closer to a 50% premium relative to where the shares were trading before spiking on M&A rumors.
Please read the full article here:
http://www.investopedia.com/stock-analysis/052113/good-deal-actavis-warner-chilcott-goes-little-cheap-act-wcrx-vrx-myl.aspx
Investopedia: A Good Deal For Actavis, But Warner Chilcott Goes A Little Cheap
0 comments:
Post a Comment
Click to see the code!
To insert emoticon you must added at least one space before the code.